Cargando…
COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study
RATIONALE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with pulmonary endothelial dysfunction. There are limited data available on the outcomes of coronavirus disease (COVID-19) in patients with pulmonary hypertension (PH), a disease characterized by pulmonar...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716894/ https://www.ncbi.nlm.nih.gov/pubmed/35549842 http://dx.doi.org/10.1164/rccm.202112-2761OC |
_version_ | 1784842788350722048 |
---|---|
author | Montani, David Certain, Marie-Caroline Weatherald, Jason Jaïs, Xavier Bulifon, Sophie Noel-Savina, Elise Nieves, Ana Renard, Sébastien Traclet, Julie Bouvaist, Hélène Riou, Marianne de Groote, Pascal Moceri, Pamela Bertoletti, Laurent Favrolt, Nicolas Guillaumot, Anne Jutant, Etienne-Marie Beurnier, Antoine Boucly, Athénaïs Ebstein, Nathan Jevnikar, Mitja Pichon, Jérémie Keddache, Sophia Preda, Mariana Roche, Anne Solinas, Sabina Seferian, Andrei Reynaud-Gaubert, Martine Cottin, Vincent Savale, Laurent Humbert, Marc Sitbon, Olivier |
author_facet | Montani, David Certain, Marie-Caroline Weatherald, Jason Jaïs, Xavier Bulifon, Sophie Noel-Savina, Elise Nieves, Ana Renard, Sébastien Traclet, Julie Bouvaist, Hélène Riou, Marianne de Groote, Pascal Moceri, Pamela Bertoletti, Laurent Favrolt, Nicolas Guillaumot, Anne Jutant, Etienne-Marie Beurnier, Antoine Boucly, Athénaïs Ebstein, Nathan Jevnikar, Mitja Pichon, Jérémie Keddache, Sophia Preda, Mariana Roche, Anne Solinas, Sabina Seferian, Andrei Reynaud-Gaubert, Martine Cottin, Vincent Savale, Laurent Humbert, Marc Sitbon, Olivier |
author_sort | Montani, David |
collection | PubMed |
description | RATIONALE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with pulmonary endothelial dysfunction. There are limited data available on the outcomes of coronavirus disease (COVID-19) in patients with pulmonary hypertension (PH), a disease characterized by pulmonary endothelial dysfunction. OBJECTIVES: To describe characteristics and outcomes of patients with precapillary PH and COVID-19. METHODS: We prospectively collected characteristics, management, and outcomes of adult patients with precapillary PH in the French PH network who had COVID-19 between February 1, 2020, and April 30, 2021. Clinical, functional, and hemodynamic characteristics of PH before COVID-19 were collected from the French PH registry. MEASUREMENTS AND MAIN RESULTS: A total of 211 patients with PH (including 123 with pulmonary arterial hypertension, 47 with chronic thromboembolic PH, and 41 with other types of PH) experienced COVID-19, and 40.3% of them were outpatients, 32.2% were hospitalized in a conventional ward, and 27.5% were in an ICU. Among hospitalized patients (n = 126), 54.0% received corticosteroids, 37.3% high-flow oxygen, and 11.1% invasive ventilation. Right ventricular and acute renal failure occurred in 30.2% and 19.8% of patients, respectively. Fifty-two patients (all hospitalized) died from COVID-19. Overall mortality was 24.6% (95% CI [confidence interval], 18.8–30.5) and in-hospital mortality 41.3% (95% CI, 32.7–49.9). Nonsurvivors were significantly older, more frequently male and suffering comorbidities (diabetes, chronic respiratory diseases, systemic hypertension, chronic cardiac diseases, and/or chronic renal failure), and had more severe PH at their most recent evaluation preceding COVID-19 diagnosis (in terms of functional class and 6-minute-walk distance; all P < 0.05). Use of pulmonary arterial hypertension therapy was similar between survivors and nonsurvivors. CONCLUSIONS: COVID-19 in patients with precapillary PH was associated with a high in-hospital mortality. The typical risk factors for severe COVID-19 and severity of PH were associated with mortality in this population. |
format | Online Article Text |
id | pubmed-9716894 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Thoracic Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-97168942022-12-05 COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study Montani, David Certain, Marie-Caroline Weatherald, Jason Jaïs, Xavier Bulifon, Sophie Noel-Savina, Elise Nieves, Ana Renard, Sébastien Traclet, Julie Bouvaist, Hélène Riou, Marianne de Groote, Pascal Moceri, Pamela Bertoletti, Laurent Favrolt, Nicolas Guillaumot, Anne Jutant, Etienne-Marie Beurnier, Antoine Boucly, Athénaïs Ebstein, Nathan Jevnikar, Mitja Pichon, Jérémie Keddache, Sophia Preda, Mariana Roche, Anne Solinas, Sabina Seferian, Andrei Reynaud-Gaubert, Martine Cottin, Vincent Savale, Laurent Humbert, Marc Sitbon, Olivier Am J Respir Crit Care Med Original Articles RATIONALE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with pulmonary endothelial dysfunction. There are limited data available on the outcomes of coronavirus disease (COVID-19) in patients with pulmonary hypertension (PH), a disease characterized by pulmonary endothelial dysfunction. OBJECTIVES: To describe characteristics and outcomes of patients with precapillary PH and COVID-19. METHODS: We prospectively collected characteristics, management, and outcomes of adult patients with precapillary PH in the French PH network who had COVID-19 between February 1, 2020, and April 30, 2021. Clinical, functional, and hemodynamic characteristics of PH before COVID-19 were collected from the French PH registry. MEASUREMENTS AND MAIN RESULTS: A total of 211 patients with PH (including 123 with pulmonary arterial hypertension, 47 with chronic thromboembolic PH, and 41 with other types of PH) experienced COVID-19, and 40.3% of them were outpatients, 32.2% were hospitalized in a conventional ward, and 27.5% were in an ICU. Among hospitalized patients (n = 126), 54.0% received corticosteroids, 37.3% high-flow oxygen, and 11.1% invasive ventilation. Right ventricular and acute renal failure occurred in 30.2% and 19.8% of patients, respectively. Fifty-two patients (all hospitalized) died from COVID-19. Overall mortality was 24.6% (95% CI [confidence interval], 18.8–30.5) and in-hospital mortality 41.3% (95% CI, 32.7–49.9). Nonsurvivors were significantly older, more frequently male and suffering comorbidities (diabetes, chronic respiratory diseases, systemic hypertension, chronic cardiac diseases, and/or chronic renal failure), and had more severe PH at their most recent evaluation preceding COVID-19 diagnosis (in terms of functional class and 6-minute-walk distance; all P < 0.05). Use of pulmonary arterial hypertension therapy was similar between survivors and nonsurvivors. CONCLUSIONS: COVID-19 in patients with precapillary PH was associated with a high in-hospital mortality. The typical risk factors for severe COVID-19 and severity of PH were associated with mortality in this population. American Thoracic Society 2022-05-12 /pmc/articles/PMC9716894/ /pubmed/35549842 http://dx.doi.org/10.1164/rccm.202112-2761OC Text en Copyright © 2022 by the American Thoracic Society https://creativecommons.org/licenses/by-nc-nd/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . For commercial usage and reprints, please e-mail Diane Gern (dgern@thoracic.org). |
spellingShingle | Original Articles Montani, David Certain, Marie-Caroline Weatherald, Jason Jaïs, Xavier Bulifon, Sophie Noel-Savina, Elise Nieves, Ana Renard, Sébastien Traclet, Julie Bouvaist, Hélène Riou, Marianne de Groote, Pascal Moceri, Pamela Bertoletti, Laurent Favrolt, Nicolas Guillaumot, Anne Jutant, Etienne-Marie Beurnier, Antoine Boucly, Athénaïs Ebstein, Nathan Jevnikar, Mitja Pichon, Jérémie Keddache, Sophia Preda, Mariana Roche, Anne Solinas, Sabina Seferian, Andrei Reynaud-Gaubert, Martine Cottin, Vincent Savale, Laurent Humbert, Marc Sitbon, Olivier COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study |
title | COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study |
title_full | COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study |
title_fullStr | COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study |
title_full_unstemmed | COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study |
title_short | COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study |
title_sort | covid-19 in patients with pulmonary hypertension: a national prospective cohort study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716894/ https://www.ncbi.nlm.nih.gov/pubmed/35549842 http://dx.doi.org/10.1164/rccm.202112-2761OC |
work_keys_str_mv | AT montanidavid covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT certainmariecaroline covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT weatheraldjason covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT jaisxavier covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT bulifonsophie covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT noelsavinaelise covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT nievesana covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT renardsebastien covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT tracletjulie covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT bouvaisthelene covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT rioumarianne covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT degrootepascal covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT moceripamela covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT bertolettilaurent covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT favroltnicolas covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT guillaumotanne covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT jutantetiennemarie covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT beurnierantoine covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT bouclyathenais covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT ebsteinnathan covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT jevnikarmitja covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT pichonjeremie covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT keddachesophia covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT predamariana covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT rocheanne covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT solinassabina covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT seferianandrei covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT reynaudgaubertmartine covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT cottinvincent covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT savalelaurent covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT humbertmarc covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT sitbonolivier covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy AT covid19inpatientswithpulmonaryhypertensionanationalprospectivecohortstudy |